Literature DB >> 11345163

HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients.

S M Sanguinetti1, F D Brites, V Fasulo, J Verona, A Elbert, R L Wikinski, L E Schreier.   

Abstract

Low density lipoprotein (LDL) oxidation is a crucial step in the atherosclerotic process. High density lipoprotein (HDL)-associated enzymes such as paraoxonase could exert a protective effect on LDL oxidation in the arterial wall, an effect which could be impaired in Type 2 diabetes mellitus (T2DM). We studied copper-induced oxidation in LDL and HDL isolated from 17 T2DM patients with fair glycaemic control and HDL-cholesterol within normal range and 17 healthy normolipidaemic control subjects. To evaluate the effect of HDL on LDL oxidation in diabetic and control subjects, we assessed copper-induced oxidation in HDL/LDL mixtures, with each lipoprotein isolated from the same subject. Relationships with HDL chemical composition, alpha-tocopherol content and serum paraoxonase activity were investigated. Oxidation was promoted by lipoprotein incubation with copper and then thiobarbituric acid reactive substances (TBARS), conjugated diene production and electrophoretic mobility in agarose gel were measured. In T2DM subjects HDL oxidation was higher than in controls. However, HDL from diabetics was as effective as control HDL to inhibit LDL oxidation. Neither HDL chemical composition nor serum paraoxonase activity showed any difference as compared to control subjects. In contrast, HDL from T2DM subjects showed a higher alpha-tocopherol content which positively correlated with HDL oxidability. Paraoxonase activity positively and strongly correlated with HDL inhibitory effect on LDL oxidation in patients and controls belonging to the heterozygous activity phenotype. Besides, LDL oxidability showed no differences between patients and controls. These results suggest that fairly-controlled T2DM patients with HDL-cholesterol levels within normal range show: 1) normal HDL ability to inhibit LDL oxidation related to normal paraoxonase activity; 2) higher HDL oxidability in spite of its high alpha-tocopherol content, which could favour tocopherol-mediated peroxidation and 3) normal LDL oxidability possibly due to the lack of significant lipoprotein structural alterations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11345163

Source DB:  PubMed          Journal:  Diabetes Nutr Metab        ISSN: 0394-3402


  6 in total

Review 1.  HDL therapy for cardiovascular diseases: the road to HDL mimetics.

Authors:  C Roger White; Geeta Datta; Zhenghao Zhang; Himanshu Gupta; David W Garber; Vinod K Mishra; Mayakonda N Palgunachari; Shaila P Handattu; Manjula Chaddha; G M Anantharamaiah
Journal:  Curr Atheroscler Rep       Date:  2008-10       Impact factor: 5.113

2.  Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.).

Authors:  C Roger White; Geeta Datta; Paulina Mochon; Zhenghao Zhang; Ollie Kelly; Christine Curcio; Dale Parks; Mayakonda Palgunachari; Shaila Handattu; Himanshu Gupta; David W Garber; G M Anantharamaiah
Journal:  Vasc Dis Prev       Date:  2009-01-01

Review 3.  Why is HDL functionally deficient in type 2 diabetes?

Authors:  Anatol Kontush; M John Chapman
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

Review 4.  Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit.

Authors:  Fernando Brites; Maximiliano Martin; Isabelle Guillas; Anatol Kontush
Journal:  BBA Clin       Date:  2017-08-19

5.  The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes.

Authors:  Sangeeta Kashyap; Karim Kheniser; Ling Li; James Bena; Takhar Kasumov
Journal:  Lipids Health Dis       Date:  2016-08-27       Impact factor: 3.876

6.  Elevated Levels of Serum β2-Glycoprotein I/Oxidized Low-Density Lipoprotein Complexes Are Associated with Cerebral Infarction in Patients with Type 2 Diabetes Mellitus.

Authors:  Limei Zhang; Yanhui Wu; Lili Qiu; Yanhong Liu; Qiang Li
Journal:  Med Sci Monit       Date:  2018-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.